Simplified methods to produce recombinant adeno-associ ated virus (ra AV) vectors are described. The AAV rep and cap genes are combined in a single recombinant adenovirus vector, i.e., a rep/cap adenovirus vector which combines in a single vector all complementing functions required for rAAV production. The replicap vectors of the present inven tion comprise: genes encoding helper functions, preferably from adenovirus, sufficient to permit AAV replication; and AAV cap and rep genes. In adenovirus replicap vectors the rep and cap genes may, for example, replace the adenovirus E3 gene or the adenovirus E1a and E1b genes.
Dec. 31, 1996 Sheet 1 of 9 Dec. 31, 1996 U.S. Patent The present invention is directed generally to the field of genetic engineering and is particularly directed to the pro duction of recombinant adeno-associated virus (AAV) vec tors for use in transducing exogenous genes into mamma lian, e.g., human cell lines. BACKGROUND Adeno-associated virus (AAV) is a single-stranded DNA parvovirus which is endogenous to the human population. Although capable of productive infection in cells from a variety of species, AAV is a dependovirus, requiring helper functions from either adenovirus or herpes virus for its own replication. In the absence of helper functions from either of these helper viruses, AAV will infect cells, uncoat in the nucleus, and integrate its genome into the host chromosome, but will not replicate or produce new viral particles.
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The genome of AAV has been cloned into bacterial plasmids and is well characterized. The viral genome con sists of 4682 bases which include two terminal repeats of 145 bases each. These terminal repeats serve as origins of DNA replication for the virus. Some investigators have also proposed that they have enhancer functions. The rest of the genome is divided into two functional domains. The left portion of the genome codes for the rep functions which regulate viral DNA replication and vital gene expression. The right side of the vital genome contains the cap genes that encode the structural capsid proteins VP1,VP2 and VP3. The proteins encoded by both the rep and cap genes function in trans during productive AAV replication.
AAV is considered an ideal candidate for use as a trans ducing vector, and it has been used in this manner. Such AAV transducing vectors comprise sufficient cis-acting functions to replicate in the presence of adenovirus or herpes virus helper functions provided in trans. Recombinant AAV (rAAV) have been constructed in a number of laboratories and have been used to carry exogenous genes into cells of a variety of lineages. In these vectors, the AAV cap and/or rep genes are deleted from the viral genome and replaced with a DNA segment of choice. Current vectors can accommo date up to 4300 bases of inserted DNA.
To produce rAAV, plasmids containing the desired vital construct are transfected into adenovirus-infected cells. In addition, a second helper plasmid is cotransfected into these cells to provide the AAV rep and cap genes which are obligatory for replication and packaging of the recombinant viral construct. Under these conditions, the rep and cap proteins of AAV act in trans to stimulate replication and packaging of the rAAV construct. Three days after transfec tion, ra AV is harvested from the cells along with adenovi Although the individual procedures currently used to make rAAV vectors are relatively simple, the processes suffer two drawbacks. Repeated transfection with the rAAV plasmid is required each time recombinant virus is to be made. Moreover, the production of raAV virus is relatively inefficient due to the inherent inefficiency of cotransfecting two plasmids into a large proportion of cells. Accordingly, new procedures for the production of raAV vectors are highly desirable.
Relevant Literature
For a general review of AAVs and of the adenovirus or herpes helper functions required, e.g., for their replication, see Berns and Bohensky (1987) , "Adeno-Associated Viruses: An Update', Advanced in Virus Research, Aca demic Press., 32:243-306. The genome of AAV is described in Laughlin et al. (1983) "Cloning of infectious adeno associated virus genomes in bacterial plasmids', Gene 23:65-73. Expression of AAV is described in Beaton et al. (1989) "Expression from the Adeno-associated virus p5 and p19 promoters is negatively regulated in trans by the rep protein ', J. Virol, . Construction of raAV is described in a number of publications: Tratschinet al. (1985) "Adeno-associated virus vector for high frequency integra tion, expression and rescue of genes in mammalian cells ', Mol Cell Biol, 5(11)3251-3260; Tratschin, et al. (1984) ', J. Wirol, 62:1963 ', J. Wirol, 62: -1973 and Samulski et al. (1989) "Helper-free stocks of recombinant adeno associated viruses: normal integration does not require viral gene expression ', J. Virol, . Cell lines that can be transformed by raAV are those described in Leb kowski et al. (1988) "Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types", Mol. Cell. Biol, 8:3988-3996. "Producer" or "packaging" cell lines used in manufacturing recombinant retroviruses are described in Dougherty et al. (1989) J. Virol, 63:3209-3212; and Markowitz et al. (1988) J. Virol., 62:1120-1124.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide tech niques and genetic constructs useful for producing AAV recombinant vectors conveniently and in large quantities.
These and other objects of the invention have been accomplished by providing the vectors, cells and methods of the present invention.
One embodiment of the present invention provides AAV/ EBV plasmid vectors comprising: an Epstein Barr virus (EBV) nuclear antigen (EBNA) gene; an EBV latent origin of replication (oriP); and a preformed adeno-associated virus (AAV) transducing vector comprising exogenous genetic material and lacking a functional AAV rep gene, and pref erably, also lacking a functional cap gene or genes. As used herein "cap gene' encompasses one or more of the genes encoding the cap proteins. Such plasmid vectors preferably 5,589,377 3 also comprise a detectable marker gene, more preferably an antibiotic resistance gene, which may be located on the AAV vector portion of the plasmid, or elsewhere on the plasmid. Often, as a result of the manner in which such plasmids are commonly constructed, there are two different marker genes, one within and one outside the AAV vector portion of the plasmid.
The present invention further provides cells and cell lines comprising an AAV/EBV plasmid vector. Such cells or cell lines are useful in methods for producing raAV. Such methods, as provided by the present invention, comprise the following steps.
Introducing into the rAAV producer cell an adenovirus vector comprising an AAV cap gene optionally under the control of an inducible promoter; and an AAV rep gens optionally under the control of an inducible promoter.
Introducing into a cell an AAV/EBV plasmid vector of the present invention to produce a raAV producer cell.
Growing the rAAV producer cell in a cell growth medium. Inducing expression of the AAV rep and cap genes, thereby producing a raAV and isolating the rAAV.
Such a method may further comprise the step of infecting the rAAV producer cell with wild type adenovirus or herpes virus, or introducing into the transfected host cell a vector comprising adenovirus or herpes virus helper functions sufficient to permit AAV replication.
In order to produce rAAV, the rAAV producer cell line must be provided with adenovirus or herpes virus helper functions and the rep and cap genes. These have traditionally been supplied by wild type adenovirus and a plasmid containing the rep and cap genes of AAV.
The present invention, however, provides two alternative approaches to more efficiently produce rAAV from raAV producer cells.
The first approach employs cells having stably incorpo rated in their genome one or more DNA sequences which together comprise the AAV rep and cap genes, and, prefer ably a detectable marker gene. Because the rep gene prod ucts may be toxic to certain cell lines, it is preferred that expression of the rep and cap genes be controlled by inducible promoters when the genes are introduced into these sensitive cell lines. The AAV/EBV vectors of the present invention are then introduced into such cells, and recombinant AAV is readily and efficiently produced by infection of the cells by a helper virus such as adenovirus or herpes virus. Once such a permanent producer cell line is produced, raAV can be produced simply, e.g., by infecting the permanent producer cell line with adenovirus.
Thus, the present invention provides a method for pro ducing raAV comprising the following steps.
Introducing one or more DNA sequences into the genome of a cell, the sequences comprising an AAV rep gene optionally under the control of an inducible promoter and an AAV cap gene, optionally under the control of an inducible promoter, thereby producing a permanent packaging cell.
Growing the permanent packaging cell in a cell growth medium.
Inducing expression (if optional inducible promoters are used) of the cap and rep genes in the permanent producer cell and introducing adenovirus or herpes virus thereby producing ra AV and isolating the rAAV.
Introducing into the permanent packaging cell an AAV transducing vector lacking a functional AAV rep gene, preferably an AAV transducing vector of the present inven tion, thereby producing a permanent producer cell. In the second approach, the AAV rep and cap genes are combined in a single recombinant adenovirus vector, i.e., a replicap adenovirus vector which combines in a single vector all complementing functions required for raAV production. The rep/cap vectors of the present invention comprise: genes encoding helper functions, preferably from adenovirus, suf ficient to permit AAV replication; and AAV cap and rep genes. In adenovirus rep/cap vectors the rep and cap genes may, for example, replace the adenovirus E3 gene or the adenovirus Ela and E1b genes.
Thus, in the second approach, raAV is produced by a method comprising the following steps.
Introducing into a cell the genome of an AAV transducing vector of the present invention which lacks a functional AAV rep gene, and, preferably lacks a functional AAV cap gene as well; thereby producing a raAV producer cell.
Growing the rAAV producer cell in a cell growth medium. Introducing into the rAAV producer cell a replicap vector of the present invention, thereby producing a transfected producer cell.
Inducing the expression of the cap and rep genes in said transfected producer cell, thereby producing raAV and isolating the rAAV.
In order to manipulate the host range and target cell specificity of raAV, the present invention further provides AAV transducing vectors having the cellular tropism of a parvovirus other than AAV. Such vectors comprise a gene encoding a cap protein of the different parvovirus, e.g., MVM(p), and exogenous genetic material. Preferably, such an AAV/EBV plasmid vector comprises: an EBNA gene; an EBV oriP; and a preformed AAV transducing vector having the cellular tropism of a different parvovirus, wherein the AAV transducing vector comprises a gene encoding a cap protein of the different parvovirus and exogenous genetic material and lacks a functional AAV rep gene. Preferably, such vectors further comprise a detectable marker gene most preferably an antibiotic gene such as hygromycin or G418 resistance. Preferably, such vectors also lack one or more, and preferably all functioning AAV cap genes. Most pref. erably, the gene encoding the cap protein of the parvovirus is located on a replicap adenovirus vector.
The present invention further provides cells comprising such AAV transducing vectors with altered cellular tropisms. The present invention also provides methods for producing rAAV as described above, in which such AAV transducing vectors with altered cellular tropisms are employed in place of those having the wild type host range of AAV.
DESCRIPTION OF THE DRAWINGS
The present invention will be better understood by refer ence to the following detailed description of specific embodiments when considered in combination with the drawings that form part of the present specification, FIG . 9 shows the steps by which recombinant AAV is produced with different capsid proteins.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS
The present invention includes a new system to produce large amounts of raAV vectors. The constructs used in the practice of the invention rely in part on the properties of Epstein Barr virus (EBV) plasmids which, in the presence of the EBV nuclear antigen (EBNA), remain as autonomously replicating plasmids in human cells. Although amplification of viral sequences using EBV vectors has previously been described, EBV plasmids have not been used in any system that generates a second virus vector, in this case the rAAV vector. Furthermore, there was no indication whether con structs containing sequences from both EBV vectors and AAV vectors would retain their desirable properties during cell reproduction or lytic production of virus.
In one method of the present invention, multiple copies of a raAV genome are permanently established in human cells as part of a chimeric AAV/EBV plasmid. To produce large amounts of raAV, these cells are infected with adenovirus or herpes virus (or appropriate recombinant constructs contain ing the required helper functions) and transfected with plasmids encoding any missing wild-type AAV rep or cap genes. Under these circumstances, lytic AAV replication ensues, and the amplified genomes are packaged as viable transducing vectors.
This method of producing raAV vectors offers several advantages over conventional procedures for producing rAAV. Permanent cell lines containing a cloned raAV genome may be used continually as a stable source of ra AV, obviating the need for relatively inefficient plasmid cotrans fections every time rAAV virus is to be made. Accordingly, production of large quantities of AAV is more easily accom plished. Furthermore, recombinant EBV plasmids, once established in host cells, are stable structurally for at least three months, and lines containing intact copies of the chimeric plasmid can be screened. Newly transfected DNA, on the other hand, suffers a very high rate of point and rearrangement mutations, and viral production systems which rely on repeated transfection of recombinant virus genomes typically have a high frequency of mutant virus. This consideration is especially important if a recombinant virus is to be used in vivo in gene therapy protocols.
The present invention provides a chimeric AAV/EBV plasmid to maintain raAV genomes at high copy number in a cell line permissive for efficient AAV reproduction; i.e., a good host for EBV plasmid vectors. This is in contrast to several studies which previously have reported that multiple copies of wild-type or raAV integrate as tandem arrays into from Detroit 6 cells upon adenovirus infection. Such a system could also be used as the starting point for the generation of IAAV. However, the present inventors have not observed tandem integration of AAV in host cells, such as human 293 cells, that are more useful in large-scale virus production. Only single copies of recombinant virus were observed in such cells, and viral "rescue' upon adenovirus superinfection was rarely seen. Therefore, the AAV/EBV chimeric vector system is more suitable for large-scale applications. With the system of the invention, production of cell clones containing multiple intact copies of the plasmid is efficient. Moreover, it allows the use of host cells, such as 293 cells, these cells were easily transfected and expressed and which produced large quantities of virus. While inte gration is possible, integrated vectors represent a less pre ferred aspect of the invention.
The original AAV/EBV chimeric vectors used in the development of the present invention contained raAV genomes which were wild type for the viral rep proteins. In every case tested, these vectors failed to remain as plasmids in host cells, regardless of the orientation of the AAV construct within the EBV vector. Plasmid maintenance was only obtained when the wild-type rep functions were elimi nated from the rAAV genome. In the presence of wild-type rep genes, the genes themselves or their encoded protein appear to have initiated EBV plasmid replication. Alterna tively, they may have interfered with the expression of the EBNA functions encoded on the plasmid which are essential for plasmid maintenance. Such negative regulation of gene expression has been observed previously for other systems. However, recent evidence suggests that in some human cell lines, expression of rep may not be detrimental to cell viability. Alternatively, the rep gene could be placed under the control of an inducible promoter. In those cells sensitive to rep gene expression, it is preferred the rep gene be placed under the control of an inducible promoter.
rAAV produced using the AAV/EBV chimeric plasmids of the invention transduces genes with high frequency into human cells. In addition, these viral stocks so produced have undetectable levels of contaminating wild-type AAV. Although the methods described herein generate viral stocks with high titers of recombinant virus, higher titers are possible. As described here, the system provides for only the transient expression of AAV rep and cap genes in order to supply needed wild-type AAV functions. This situation can be optimized for the production of AAV cap proteins which are required stoichiometrically for the production of raAV. There are relatively few limitations on the rAAV vector. The complete AAV genome should not exceed 4700 base pairs. The two terminal repeats (origins of replication) of AAV must be present in the construct. There is no limitation on the nature of the exogenous genetic material that is included in the recombinant plasmid vector.
The recombinant AAV/EBV vectors of the present inven tion comprise, a raAV vector and an effective amount of EBV DNA, an amount of EBV DNA defined as sufficient genetic material from EBV to allow the recombinant plas mid to function in the manner described herein. Minimally, this includes a genetic region encoding EBNA and an EBV oriP. Other regions of EBV can be present, but are not required.
The recombinant replicap adenovirus vectors of the present invention, as described below in Example 7, contain the rep and cap genes of wild type AAV and all elements of adenovirus required in trans to produce rAAV. Alternatively, elements required in trans (i.e., E1a and E1b) may be deleted and subsequently supplied by the host cell line. For example, 293 cells are useful for this purpose since they express Ela and E1b constitutively.
Alternatively, the rep and cap genes may be stably inte grated into the genome of the cell line.
The recombinant vectors of the present invention may be introduced into host cells by any of the conventional means well known in the art, e.g., by transfection methods described previously for transforming cells with EBV. Like Additionally, it is necessary to provide any missing AAV genes, such as those encoding rep or cap proteins, that have been deleted from the AAV recombinant vector. This is typically done by transfecting the host cell line with a plasmid containing the appropriate genetic material, which may include cap genes orportions thereof from parvoviruses other than AAV in order to alter the host specificity of the rAAV, as described in greater detail in Example 8 below.
Specific examples of the individual steps described above are set forth in the following examples. However, it will be apparent to one of ordinary skill in the art that many modifications can be made, and that the examples are provided for purposes of illustration only and are not lim iting of the invention unless so specified. EXAMPLE 1.
Plasmid Constructions
All DNA manipulations and plasmid constructions were performed using standard procedures. 
Cells: growth and maintenance
Human 293 cells (ATCC CRL 1573), were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS) and 100 U/ml penicillin and streptomycin. Cells were grown in a humidified 37° C. incubator supplemented with 5% CO. Selection of hygro mycin B resistant 293 cells usually started 3-5 days after transfection with AAV/EBV chimeric plasmids.
K562 cells were grown in RPMI containing 10% FCS and 100 U/ml penicillin and streptomycin. K562 cells were infected with raAV stocks as described by Lebkowski et al. (1988) , except that 1x10 K562 cells were incubated with 5 ml of any given viral stock. Viral infection efficiencies were determined by monitoring G418 resistance frequencies in the manner described by Lebkowski et al. (1988) .
To start the drug selection process, the culture medium was withdrawn from the cells and fresh medium containing either 200 ug/ml hygromycin B or 1 mg/ml G418 was added. The procedure was repeated every 2-3 days until the selec tion process was complete. 293 cells containing chimeric AAV/EBV plasmids were constantly maintained in culture medium containing the appropriate selective drug. 
Transfection of Cells with Recombinant Plasmids and Evaluation of Transfected Cells
All three AAV/EBV chimeric vectors described in Example 1 were transfected into human 293 cells, and stable drug-resistant cell lines were selected. 293 cells containing p220ARCMSVapo 14 and 15 were selected in the presence of hygromycin B, whereas cells transformed by p220SMneo were selected using the drug G418 as described in Example 5,589,377 9 2. Individual drug-resistant clones containing each construct were grown to mass culture and used for experimentation. Pools of greater than 100 individual 293 cell clones were also made to represent a population of drug resistant clones. These pools are referred to as "populations."
Cells transformed by the three AAV/EBW constructs were examined for autonomously replicating chimeric plasmid. In these experiments, small molecular weight DNA was extracted from selected cell lines using the procedure described by Hirt (1967) Escherichia coli strain HB101, and transformed bacteria were selected in the presence of ampicillin. Plasmid DNA was isolated from cultures inoculated with individual bac terial colonies and was characterized by restriction enzyme analysis on polyacrylamide gels.
Plasmid p220SMneo could be rescued from G418, resis tant 293 cells and reintroduced into E. coli. The plasmid DNA that was isolated from individual bacterial colonies transformed with small molecular weight DNA from 7 individual and one population of p220SMneo 293 cells could be seen on the gels. At the time of the Hirt extraction, these G418 resistant 293 cells had been in culture for over 2 months. In all instances, HindIll restriction analysis of the isolated plasmids yielded DNA fragments of the expected length of 0.5, 2.8 and 9.7 kb. Such results indicate that p220SMneo was maintained as a plasmid in the G418 resistant 293 cells. The rescued plasmids were also identical in size and restriction analysis to the original p220SMneo, suggesting that the plasmid did not undergo major rear rangements during its residence in the mammalian cells. These observations were verified by Southern blot analysis of HindIII-restricted, small molecular weight DNA isolated from the various G418-resistant 293 cells.
Similar analysis was performed on hygromycin-B-resis tant 293 cell clones and populations that were generated using the plasmids p220ARCMSVapo 14 and 15. As above, this analysis was performed on hygromycin-B-resistant 293 cells that had been in culture for over 2 months. The HindIll restriction digests of plasmid DNA isolated from bacterial colonies transformed by small molecular weight DNA from hygromycin-resistant 293 cells could be seen in the gels, as could the plasmid rescued from two p220ARCMSVapols 293 cell clones. Again, in all of the cases, intact plasmid could be rescued from the p220ARCMSVapo 14 and 15293 cells. In one instance, in clone 15-3, an additional deleted version of p220ARCMSVapo 15 was also observed, believed to represent a deletion which occurred shortly after transfection.
To date, such analysis has been performed on 10 clones and 2 populations of drug-resistant 293 cells produced by p220SMneo and on 3 clones and 2 populations produced by p220ARCMSVapo 14 and 15. In all instances, unrearranged plasmid could be rescued from the mammalian cells even after two months in culture. Moreover, in 15 out of 17 drug resistant cell lines tested, only unrearranged plasmid was 
Production of AAV virus
In order to determine whether a switch to lytic AAV replication would ensue if the appropriate AAV helper factors were supplied, we performed the following experi ment. Human 293 cells containing AAV/EBV chimeric vectors were plated out 2 days before virus generation into fresh medium lacking hygromycin B. These cells were seeded into cultures such that on the day of virus production, the cells were approximately 25-40% confluent on 100-mm culture dishes. To produce recombinant virus, these cells were infected with adenovirus 2 stocks (multiplicity of infection of 1 to 5) for 2-4 hours. The cells were then transfected with 20 ug pBal using calcium phosphate medi ated coprecipitation according to the method described by Wigler et al., "Transformation of Mammalian Cells with Genes From Procaryotes and Eukaryotes", Cell 16:777-785.
The next day the medium was withdrawn and replaced with 5 ml of fresh medium lacking hygromycin B. Two days later, the cytopathic effect of adenovirus was evident, and raAV virus stock was harvested.
To harvest virus, the cells and medium were collected, and the cells were completely lysed by two 1-sec pulses of sonication. The viral stock was cleared of cellular debris by centrifugation and adenovirus was inactivated by heating the stock at 56° C. for one hour. Before use, the stock was filtered through a 1 micron cellulose acetate membrane.
Small molecular weight DNA was collected from cells using the procedure of Hirt (1967) . This DNA was purified by treating the Hirt lysate with 10 g/ml proteinase K followed by sequential extractions with phenol and phe nol:chloroform: isoamyl alcohol (25:24:1). The purified DNA was then concentrated by ethanol precipitation and used as described. For Southern blots, the DNA was run on 0.8% agarose gels and blotted onto nylon membranes according to the manufacturer's instructions (Hybond N+; Amersham). The blots were probed with DNA fragments labeled by the random priming method according to the manufacturer's instructions (Pharmacia, Piscataway, N.J.). After aqueous hybridization at 65° C., the filters were washed at 65° C. with solutions of increasing stringency concluding with 0.1XSSC (15 mM NaCl, 1.5 mM sodium citrate pH 7.0)+1.0% SDS. Autoradiograms were produced by exposure to X-ray film (type XAR; Eastman Kodak Co.
Rochester, N.Y.).
For the analysis of the episomal nature of chimeric AAV/EBV plasmids in 293 cells, small molecular weight DNA was isolated from cells using the Hirt procedure as described above and transformed into E. coli strain HB101.
Small-scale preparation of plasmid were purified from 1 ml cultures of single bacterial colonies. Plasmid characteriza tion was performed by restriction enzyme analysis.
The results obtained showed that when cells containing p220ARCMSVapo 14 or 15 plasmid were infected with adenovirus and transfected with pBal, lytic replication of the AAV construct began. This event was evidenced by the appearance of a 2.8 kb band which hybridizes to an apoA1 probe. This 2.8 kb band is the correct, size for the recom binantARCMSVapogenome cloned into p220ARCMSVapo 14 and 15. Also visible was a ladder of faint bands starting at 5.6 kb. These bands represent multimers of the rAAV genome which are known to be intermediates in AAV replication.
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The appearance of the 2.8 kb raAV genome is completely dependent on the presence of wild-type AAV helper func tions. If these same cells were simply infected with aden ovirus or infected with adenovirus and transfected with the rep deletion mutant pSCap, no ARCMSVapo replication was observed. Moreover, the amplification of the rAAV construct was dependent on the presence of the AAV/EBV chimeric plasmid. Parental 293 cells which lack the AAV/EBV chi meric vector showed no ARCMSVapo amplification even in the presence of both wild type AAV functions. To date, a total of six p220ARCMSVapol4 and eleven p220ARCMSVapolis clones have been tested. In every instance, replication of the rAAV construct occurred when the cells were supplied with adenovirus and wild-type AAV functions. Moreover, such amplification did not depend on the orientation of the IAAV construct in the EBV vector.
Both orientations led to similar levels of ARCMSVapo amplification.
Lytic replication of the rAAV construct can also be initiated in cell clones containing p220SMneo. Analysis of transfected cells for recombinational events
The AAV constructs in p220ARCMSVapol4, 15, and p220SMneo have all but 1350 bases of wild-type AAV DNA deleted. They are defective for both the rep and cap func tions of AAV. The plasmid pBal, which is used to supply the rep and cap AAV functions, is wild type for all AAV sequences except for deletions of 121 bases in each 145 base terminal repeat. As a result, the AAV construct in peal is defective for the cis functions necessary for AAV viral replication. One important question in these studies was whether recombinational events occur between the con structs and p3AL during raAV replication sufficient to generate replicating wild-type AAV genomes.
To answer this question, cell clones containing either p220ARCMSVapol4, 15, or p220SMneo were infected with adenovirus and transfected with pBal. Forty-eight hours later, Hirt extracts of these transfectants were made and analyzed for the presence of raAV and wild-type AAV sequences.
As outlined above, such treatment of the AAV/EBV chimeric vector cell clones induces amplification of the rAAV construct as evidenced by the appearance of the appropriate recombinant genomes of 2.8 and 4.1 kb. When these same Southern blots were reprobed with the AAV capsid gene, no bands corresponding to the 4.7 kb, wild-type genome were observed. The only hybridizing sequences sometimes observed correspond to those from residual psal plasmid DNA remaining in the cells after transfection. Support for this conclusion comes from the observation that these residual super-coiled, nicked, and linear pBal bands can also be observed after identical treatment of parental 293 cells. Therefore, during the greater than 10,000-fold ampli fication of the rAAV construct, no detectable production of the wild-type genome was observed. EXAMPLE 6 Analysis of raAV virus produced by the method of the invention Viral stocks produced from p220SMneo cell clones infected with both adenovirus and pBal were tested for the presence of transducing recombinant ASMneo virus. In these experiments, K562 cells, from a human leukemia line, were infected with pASMneo and selected for the presence of the neomycin phosphotransferase gene. Table 1 shows the results of three such experiments. Ten of the eleven of the cell lines tested produced raAV which was capable of infecting K562 cells and stably producing G418 resistant K562 clones. Infection efficiencies varied somewhat from experiment to experiment ranging from 0 to 1.0%. There was also some variability in the viral titers of stocks produced from the various p220SMneo cell clones. For instance, recombinant virus stocks produced from cell lines 220SMneo4 routinely produced higher infec tion efficiencies than those from the other cell clones.
Recombinant virus produced from p220SMneo and p220ARCMSVapol5 clones are also capable of coinfection. K562 cells were coinfected with ASMneo and ARCMSVapo stocks that were produced as described as above. G418 resistant clones were selected, pooled, and screened for the secretion of apolipoprotein A1. In one such experiment, these and control K562 cells were labeled with S-methion ine, and the cell culture supernatant was immunoprecipitated with a polyclonal anti-apoA1 antibody. Briefly, coinfected cells were labeled for 4 days in standard medium containing 200 uCi S-methionine. At this point, the culture medium was cleared of cells by centrifugation and incubated with 100 ul of protein-A-conjugated agarose beads (Repligen) which had been previously coated for 3 hours with an excess of anti-human apolipoprotein A1 rabbit antiserum (Boe hiringer Mannheim). The cell culture medium bead mixture was incubated overnight at 37°C. using gentle rotation. The following morning, the beads were collected and washed two times by centrifugation. Bound proteins were released using Laemmli sample buffer and analyzed on 15% SDS/ PAGE gels according to the method of Laemmli (1970) Nature, . Cell culture proteins which were immunoprecipitated were visualized by autoradiography of the dried gel.
Analysis of the immunoprecipitates indicates that apoli poprotein A1 was secreted from the cells coinfected with the two viral stocks. Control K562 cells did not secrete this protein. These combined experiments indicated that raAV virus produced by this simplified method can be used to easily transduce one or two genes into single cells. In the context of these vectors, the transduced genes are properly expressed and their proteins appropriately targeted to vari ous cell compartments. EXAMPLE 7 Construction of efficient systems to deliver wild type AAV rep and cap functions to the rAAV producer cell line.
In order to produce raAV virus from cell lines, the cell As a second approach, the rep and cap genes are incor porated in a recombinant adenovirus vector to form a replcap adenovirus vector which can efficiently deliver genes to human cells.
The recombinant adenovirus vector provides viral helper functions and carries the AAV rep and cap genes.
The rep/cap adenovirus vectors of the present invention are constructed by the following methods. A preferred means for constructing such vectors is by deleting the adenovirus E1a and E1b genes from the 30 kb adenovirus genome and replacing them with the AAV rep and cap genes as depicted in FIG. 5 In another approach to the construction of a replicap adenovirus vector, sequences containing the replicap genes of AAV replace the nonessential E3 region of adenovirus by recombinant DNA techniques. For example, an Xbal frag ment containing the replicap genes of paAV/Ad is cloned into the Xbal site of pFGdx, which contains a portion of the adenovirus genome from map units 59.5 to 100 with a deletion of the E3 region of the virus, as shown in FIG. 7 . An alternative to pFGdx is a Ball fragment from paV2 with appropriate added Xbal linker.
Alternatively, the recombinant rep/cap adenovirus is cre ated by cotransfecting into 293 cells pFGdx along with an EcoRI fragment of Adenovirus 5 which contains map units 1 to 60 of the virus. Plagues appearing after 1 to 14 days arise after recombination between the two transfected DNAs and replication of the recombinant replicap adenovirus. Indi vidual plaques are picked, amplified and checked by PCR for the integrity of their sequence. The recombinant virus is finally tested for its ability to deliver and express the rep and cap genes in 293 cells. Expression of rep and cap genes is analyzed as described above.
Alternatively, the replicap sequences are inserted any where within adenovirus by recombinant cloning means provided that the interrupted or deleted adenovirus functions are complemented in trans in the host cell.
